Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON plc (ICLR) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Ireland, ICON specializes in the strategic development, management, and analysis of clinical programs that support clinical development from compound selection to phase I-IV clinical studies.
Operating in a highly fragmented industry, ICON is among a select group of organizations with the capability and expertise to conduct clinical trials and development projects on both a local and global scale. The company's core services are versatile, offering both standalone and integrated full-service solutions to meet diverse client needs. This operational flexibility ensures that ICON can tailor its services to individual project requirements.
ICON's array of services includes end-to-end pharmacovigilance, which covers post-marketing surveillance activities. The company also provides ancillary services, such as laboratory and imaging capabilities, enhancing its comprehensive approach to drug development and clinical research.
This robust service offering positions ICON as a pivotal partner for firms aiming to bring their medical innovations to market. Recent achievements and ongoing projects underscore ICON's commitment to excellence and innovation in clinical research. The company's financial health remains strong, supported by strategic partnerships and a global client base.
Stay updated on ICON plc's latest developments, performance updates, and industry news to understand the significant role this organization plays in advancing healthcare solutions worldwide.
ICON (NASDAQ: ICLR) will host its 2024 Investor Day in New York City, featuring presentations from its executive team outlining strategic initiatives and financial outlook. ICON updated its 2024 guidance, expecting adjusted earnings per share (EPS) to range between $14.75 and $15.25, representing a 15.3% to 19.2% increase over 2023. Full-year revenue is projected to be between $8,480 million and $8,720 million, marking a 4.4% to 7.4% year-over-year increase. The company has also refined its debt structure, including a $2 billion bond offering and Term Loan B repricing, which is expected to result in a net interest expense of $200-$210 million in 2024.
ICON, a leading healthcare intelligence and clinical research organization, has announced an Investor Day event on May 30, 2024, in New York City. Starting at 10 AM ET, the event will feature presentations from ICON's executive team and a question-and-answer session, concluding around 1 PM ET. A live webcast of the event will be available on ICON's Investor section of their website. Any updates or changes will also be posted there.
ICON plc, a healthcare intelligence and clinical research organization, released its ICON Cares 2023 Report. The report highlights the company's achievements in ESG, diversity, inclusion, and sustainability goals. ICON received recognition for its efforts, including a gold medal status from EcoVadis and being named one of Europe's Climate Leaders in 2024. The company focused on increasing access to clinical trials, promoting workplace diversity, conducting business sustainably, and supporting communities.
ICON plc announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of three tranches with varying maturity dates. The Notes will be issued by ICON's subsidiary and guaranteed by ICON and its subsidiaries. The offering is expected to close on May 8, 2024, with proceeds used to repay existing debt and cover related expenses.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
What services does ICON plc provide?
Where is ICON plc headquartered?
What is ICON's role in pharmaceutical development?
Does ICON offer standalone and integrated services?
What is pharmacovigilance, and does ICON provide it?
What industries does ICON serve?
What makes ICON a leader in its industry?
How can I stay updated on ICON's latest news and developments?
What are some of ICON's ancillary services?
What type of clients does ICON work with?
